Keyword: Johnson & Johnson
With just-arrived competition in mantle cell lymphoma, J&J’s Imbruvica has snagged reimbursement backing in an important new market.
Pfizer now has a second FDA-approved biosimilar version of Remicade. Don't expect a sales boost from Ixifi, though. Pfizer has no plans to launch it.
Created by Janssen along with the American Cancer Society, Cancer Support Community and CancerCare, the website was years in the making.
J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.
J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.
JLABS lands first ex-North America site in Shanghai, Sanofi's Dengvaxia situation quickly worsens in the Philippines, Astellas buys DMD biotech.
Merck's appeal to the Supreme Court has drawn in the U.S. Solicitor General, and the outcome could reverberate across the pharmaceutical industry.
Recent years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class med may still be on its way, one analyst says.
It’s an A-plus for J&J and Sanofi. The second annual Good Pharma Scorecard assigned both drugmakers perfect scores of 100% for trial transparency.
After three wins in cases over the risks of blockbuster blood thinner Xarelto, Bayer and Johnson & Johnson have encountered their first defeat.